India’s medical-device industry is rapidly evolving, moving from import dependence to indigenous innovation. One company positioning itself at the center of this transformation is S3V Vascular Technologies Limited.
Founded with a focus on cardiovascular and critical-care technologies, the company is developing advanced interventional devices while also attempting to reduce treatment costs for patients. With breakthrough products, strategic funding, and expansion plans underway, S3V is emerging as a serious player in India’s MedTech ecosystem.
Founded in 2011 and headquartered in Mysore, Karnataka, S3V Vascular Technologies focuses on the development and manufacturing of advanced medical devices used in cardiovascular procedures and critical-care treatments.
The company operates a fully integrated MedTech model combining:
In-house research and development
Proprietary product technologies
Regulated medical-device manufacturing
Its products are supplied to hospitals, clinicians, and distributors across India and international markets.
One of its most notable achievements came recently when the company secured regulatory approval for a titanium-based expandable spinal cage, making it the first company globally to receive a manufacturing license for such a device.
S3V manufactures a range of high-end interventional medical products used in cardiovascular and neurological procedures.
The company produces multiple types of vascular stents, including:
Drug-Eluting Stents (DES)
Bare-Metal Stents
Esophageal Stents
Biliary Stents
These devices are widely used in minimally invasive procedures to keep arteries or ducts open.
S3V also manufactures specialized catheters such as:
PTCA Catheters
Neurovascular Catheters
These products play a key role in angioplasty and neurovascular interventions.
A major innovation from the company is India’s first indigenous Mechanical Thrombectomy Device designed for the treatment of brain strokes. The device is expected to significantly lower treatment costs in India.
Despite technological progress, the company’s recent financial performance has been volatile.
Particulars | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 19.0 | 15.0 | 13.5 |
| Gross Margin (%) | 58.4 | 63.3 | 74.8 |
| EBITDA | 3.7 | 2.5 | -0.6 |
| OPM (%) | 19.5 | 16.7 | -4.2 |
| PBT | 0.7 | -3.1 | 0.2 |
| PAT | 0.6 | -3.2 | 0.1 |
| PAT Margin (%) | 2.9% | -21.3% | 0.4% |
Revenue has declined over the last three years.
Gross margins improved significantly, indicating better product mix or pricing power.
Profitability has remained inconsistent, with losses in FY24 and minimal profits in FY25.
This suggests the company is still in an investment and product-development phase.
The company is led by Badari Narayan, a veteran in India’s medical-device industry.
He brings over 30 years of experience and has played a role in developing affordable cardiac stent technologies in India. Notably, he has collaborated with Dr. A.P.J. Abdul Kalam on low-cost cardiac stents.
Name | Role | Experience |
|---|
| Badari Narayan | Promoter | 30+ years in MedTech innovation |
|---|
| Dr. Vijaya Gopal | Head of R&D | MBBS, leading product development |
|---|
| Vishnu Shreyas N.G | Head of Operations | Engineer managing manufacturing operations |
|---|
The promoter has been involved in several major stent innovations over the years:
1999: 316LVM stents
2004: Cobalt-Chromium stents
2005: Paclitaxel Drug-Eluting Stents
2006: Sirolimus DES and PTCA catheters
These milestones reflect deep technical expertise in interventional cardiology devices.
In March 2024, S3V raised ₹110 crore in a strategic funding round.
Particulars | Details |
|---|
| Amount Raised | ₹110 Cr |
|---|
| Pre-Money Valuation | ₹228 Cr |
|---|
| Post-Money Valuation | ₹338 Cr |
|---|
| Share Price | ₹176 per share |
|---|
The company plans to deploy the capital toward:
Debt reduction
Working capital requirements
Expansion of manufacturing facilities
This funding also strengthened the company’s balance sheet ahead of future growth.
In May 2025, the company became the first in the world to receive regulatory approval from CDSCO for a titanium-based expandable spinal cage branded as 3V Vajra.
This device is used in spinal fusion surgeries and represents a significant technological advancement.
The company has also developed India’s first indigenous mechanical thrombectomy kit.
This innovation could significantly lower stroke treatment costs:
Treatment | Typical Cost |
|---|
| Imported thrombectomy systems | ~₹10 lakh |
|---|
| S3V indigenous device | ~₹1 lakh |
|---|
If successfully adopted, this could dramatically expand stroke-care accessibility in India.
To scale its neurovascular device business, the company is building a new neuro division facility in Chennai.
Key details:
Land area: 12 acres
Focus: Neurovascular device manufacturing
Commercial production expected in Q4 FY26
This facility could become a major growth driver for the company in the coming years.
India’s medical-device industry is still heavily dependent on imports. Companies like S3V Vascular Technologies are attempting to change that by building indigenous high-end technologies.
With innovations in stents, neurovascular devices, and spinal implants, along with strong investor backing, the company is positioning itself as a future MedTech disruptor.
However, the key challenge ahead will be scaling revenues and achieving consistent profitability while expanding globally.
If successful, S3V could emerge as one of India’s most important homegrown medical-device companies over the next decade.